CLL Coverage from Every Angle

Multi-hit TP53-Aberrant CLL: Focus on Prognostication and Management

By: Jenna Carter, PhD
Posted: Friday, July 16, 2021

A recent article published in Clinical Cancer Research reported on the clinical effects of ibrutinib in patients with multi-hit TP53-mutated chronic lymphocytic leukemia (CLL). Carsten U. Niemann, MD, PhD, of Copenhagen University Hospital, and colleagues focused on TP53 mutations, as they confer resistance to chemoimmunotherapy and are often considered a predictor of poor disease outcomes. Their findings revealed that overall survival, progression-free survival, and time to disease progression were shorter in patients with multi-hit TP53 aberrations.

“Although currently considered equal prognostic markers, patients treated with single-agent ibrutinib carrying only a single TP53 hit [del(17p) or a TP53 mutation] demonstrate excellent progression-free and overall survival on ibrutinib…,” stated the study authors. “An assessment of TP53 aberrations by using both FISH [fluorescence in situ hybridization] and deep NGS [next-generation sequencing] should be performed in all CLL patients considered for treatment with ibrutinib.”

A total of 51 patients with TP53-aberrant CLL in a phase II study of single-agent ibrutinib (420 mg/day) were included in this study. Patients were separated by the number of TP53 aberrations: single hit TP53 (n = 9) and multi-hit TP53 (n= 42). Single-hit and multi-hit TP53 were defined as having one TP53 aberration [del(17p) or a single TP53 mutation] and more than one TP53 aberration [del(17p) and TP53 mutation(s); or multiple TP53 mutations].

Results revealed that patients with multi-hit TP53 demonstrated poorer overall survival and progression-free survival than those with single-hit TP53 or no known aberration (P = .002). Additionally, mutations were enriched among patients with advanced Rai stage relapsed or refractory disease compared with treatment-naive patients (P = .006). Furthermore, multi-hit TP53 CLL was found to be independently associated with poorer progression-free survival and time to disease progression. Based on these findings, the authors concluded that although ibrutinib was successful in prolonging progression-free survival in the single-hit group, further testing is needed for the multi-hit population.

Disclosure: For full disclosure of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.